ArticleBMC psychiatry2026
Insomnia, proteomic characteristics, and mortality risk in depression: a UK Biobank study.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough insomnia is associated with increased mortality in patients with depression, the underlying biological pathways remain unclear. As functional gene products, proteins are well suited to bridge behavioural risk factors and clinical outcomes.
objectiveTo explore the associations between insomnia, proteomic characteristics, and mortality risk in depressed individuals.
methodsWe included 4,498 patients with depression from the UK Biobank. Insomnia was self-reported; all-cause mortality was the primary outcome. Cox models, LASSO regression, single- and multi-mediator joint mediation analyses, subgroup analyses, competing-risk analyses, and incremental predictive value assessments were performed.
results"Usually insomnia" was an independent predictor of increased mortality (HR = 1.38, 95% CI: 1.05-1.81) and was associated with a 2.3-year shorter life expectancy at age 45. Twenty insomnia-related proteins were identified via LASSO regression and used to construct a proteomic signature, which was significantly associated with mortality (T3 vs. T1: HR = 2.54, 95% CI: 1.95-3.32). Multi-mediator joint analysis revealed that these 20 proteins collectively accounted for 37.2% of the total effect of insomnia on mortality, among which TNFRSF6B, CSTB, and LGALS4 retained statistically significant independent mediating contributions. The proteomic signature demonstrated significant incremental predictive value beyond conventional clinical risk factors.
conclusionInsomnia is associated with increased mortality risk in depressed patients. Multi-mediator analysis identified three proteins (TNFRSF6B, CSTB, and LGALS4) as independent mediators of this association. The insomnia-related proteomic signature may serve as a biomarker for mortality risk stratification. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.